Treg Therapy Market

Treg Therapy Market Overview

The global treg therapy market size, valued at USD 22 million in 2025, is projected to reach USD 47 million in 2026 and USD 442 million by 2035, representing a CAGR of 28.1% during the forecast period.

To learn more about this report, request a free sample copy

Given the various benefits offered, including high target specificity, customization potential and ability to generate immunological memory, regulatory T cells (Treg) therapies have garnered significant attention among key industry stakeholders for the treatment of various oncological and non-oncological disease indications. The National Cancer Institute (NCI) has estimated that, by 2030, over 22 million individuals are likely to be diagnosed with some form of cancer in the US alone. As a result of the growing patient population affected by this disease, there is a rise in the demand for effective treatment modalities.

The conventional approaches, such as chemotherapy, surgery and radiation therapy, employed for the treatment of oncological indication(s) are considered to be inadequate, specifically for late-stage cancers. Therefore, in recent years, the focus of the research community has shifted towards the development of novel treatment modalities, such as Treg cell therapies, that exhibit high efficacy. The Tregs are a mature subpopulation of regulatory T-cell therapy that play a critical role in mediating immunological tolerance to self-antigens and suppress immune responses that are harmful to the host, thereby, enabling a balance to homeostasis. In recent years, Treg based therapies have become a research hotspot in the field of immunotherapy due to their ability to prevent / delay graft rejection and control autoimmune responses generated post adoptive transfer in vivo.

Over time, more than 90 pharmaceutical companies and academic / research institutes have undertaken various initiatives to develop effective Treg cell therapies against multiple target indications. At present, the pipeline features close to 95 product candidates, and this number is anticipated to grow further in the foreseen future. Of the total candidates, more than 15 Treg therapies, including ALS001 (Coya Therapeutics), CLBS03 (Caladrius Biosciences), ILT-101 (ILTOO Pharma), NKTR-358 (Eli Lilly) and RGI-2001 (REGiMMUNE), are currently being evaluated in advanced stages of development. The growing interest of pharmaceutical stakeholders in Treg therapy market is also reflected from the recent rise in clinical trials being registered for such candidates. Moreover, multiple collaborations have been inked between both industry and non-industry players in order to advance the development of various pipeline candidates, over the past decade. It is also worth highlighting that, in the last five years, capital investments worth around USD 3 billion have been made by strategic investors in Treg therapy market. We believe that this niche, but upcoming market, is poised to witness a healthy pace market growth during the forecast period, with pioneers in the field likely to benefit from the first-to-market advantage.

Key Companies in Treg Therapy Market

Examples of key companies engaged in Treg therapy market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Abata Therapeutics, Cellenkos, Coya Therapeutics, ILTOO Pharma, NEKTAR, Roche, Sonoma Biotherapeutics, TeraImmune and TRACT Therapeutics. This market report includes an easily searchable excel database of all the companies developing Treg therapies such as CAR Treg and others, worldwide.

Recent Developments in Treg Therapy Market:

Several recent developments have taken place in the field of Treg therapy market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In February 2026, Kincell Bio entered into a collaboration with RegCell to advance RegCell’s Treg cell therapy platform, with Kincell providing process and analytical development and GMP manufacturing support around RegCell’s lead antigen specific Treg product for autoimmune hepatitis.
• In January 2026, TRexBio closed an oversubscribed USD 50 million financing to advance its growing clinical stage pipeline of tissue targeted regulatory T-cell therapeutics, including TRB-061 for atopic dermatitis now in Phase 1a/b and two additional programs toward the clinic.
• In October 2025, Zag Bio emerged from stealth with an USD 80 million Series A round led by T1D Fund and Polaris Partners, with AbbVie, Regeneron and Sanofi participating to advance thymus targeted Treg based medicines for autoimmune diseases including Type 1 diabetes.

Scope of the Report

The “Treg Therapy Market: Industry Trends and Global Forecast, till 2035” market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities for the Treg therapy market. The market research report highlights efforts of both industry players and academic organizations. Amongst other elements, the market research report features the following:

• A detailed overview of the current market landscape of Treg cell therapies, along with information on several relevant parameters, such as type of product (Tregs, interleukin 2, monoclonal antibodies, small molecules and others), phase of development (preclinical / discovery, phase I, phase I/II, phase II, phase II / III and phase III), therapeutic area (autoimmune disorders, oncological disorders, post-transplant infection, neurological disorders, metabolic disorders, dermatological disorders, infectious diseases, and others), target indication (diabetes mellitus, graft vs host diseases, post liver transplant infection, post kidney transplant infection, amyotrophic lateral sclerosis, multiple sclerosis, myelodysplastic syndromes, atopic dermatitis and acute myeloid leukemia), source of T-cells (autologous and allogeneic), route of administration (intravenous, subcutaneous biologics and intramuscular), dose frequency (multiple dose and single dose), target patient segment (children, adults and elderly patients), type of treg cell therapy (monotherapy and combination therapy) and type of developer (industry and non-industry). In addition, it presents details of the companies developing Treg cell therapies, highlighting their year of establishment, company size, location of headquarters and most active players (in terms of number of pipeline candidates).
• An in-depth analysis of completed, ongoing and planned clinical studies of various Treg cell therapies, based on various relevant parameters, such as trial registration year, enrolled patient population, trial phase, trial recruitment status, study design, average time taken, target patient segment, gender of enrolled patients, type of sponsor / collaborator, leading industry players (in terms of number of trials conducted) and regional distribution of trials.
• An analysis of the recent partnerships inked between various players engaged in Treg therapy market, during the period since 2015 (till August). Additionally, it includes a brief description of various types of partnership models (such as R&D agreements, product development and commercialization agreements, licensing agreements, acquisitions, clinical trial agreements, and manufacturing agreements) that have been adopted by stakeholders, during the given period.
• A detailed analysis of various investments, such as seed financing, venture capital financing, capital raised from IPOs and subsequent public offerings, grants and debt financing that were undertaken by companies engaged in Treg therapy market, during the period since 2015.
• Detailed profiles of clinical stage Treg cell therapies (phase I/II or above); each profile features an overview of the treg cell therapy, along with information on clinical trials and its endpoints, dosage regimen, key insights and estimated sales revenues (if available).
• A qualitative analysis, highlighting the five competitive forces prevalent in Treg therapy market, including threats for new entrants, bargaining power of suppliers, bargaining power of buyers, threats of substitute products and rivalry among existing competitors.
• Elaborate profiles of prominent players engaged in the development of Treg cell therapies. Each profile features a brief overview of the company, details related to its financials (if available), product portfolio and recent developments.

The key objective of Treg therapy market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for Treg therapy market during the forecast period. The market report also includes likely sales forecasts of Treg cell therapies that are in the mid to late stages of development. Additionally, it features market size projections for the overall Treg cell therapies market, wherein both the current and upcoming opportunity is segmented across [A] target indication (Crohn Disease, Bipolar Disorder, Allergic Rhinoconjunctivitis, COVID 19, Diabetes Mellitus, Systemic Lupus Erythematosus, Alzheimer Disease and Graft Vs Host Disease), [B] key players and [C] key geographies (North America, Europe and Asia Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.

The opinions and insights presented in this market research report were influenced by discussions conducted with stakeholders in Treg therapy market.